Skip to main content
. Author manuscript; available in PMC: 2024 Feb 3.
Published in final edited form as: Cancer Immunol Res. 2023 Aug 3;11(8):1114–1124. doi: 10.1158/2326-6066.CIR-22-0996

Figure 1. Study design of the clinical trial and correlative analysis evaluating the combination of atezolizumab and bevacizumab in variant histology RCC and any RCC with sarcomatoid features.

Figure 1.

Abbreviations: BP: Blood pressure, C1D1: Day 1 of Cycle 1 of treatment, C3D1: Day 1 of Cycle 3 of treatment, ccRCC: clear-cell renal cell carcinoma, ECOG-PS: Eastern Cooperative Oncology Group Performance Status, FFPE: Formalin-Fixed Paraffin-Embedded, ORR: overall response rate, RCC: renal cell carcinoma, RECIST: Response Evaluation Criteria in Solid Tumors.